Preclinical animal studies in ischemic stroke: Challenges and some solutions.

Autor: Narayan SK; Comprehensive Stroke Care and Neurobiology Centre, Department of Neurology Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry India., Grace Cherian S; Comprehensive Stroke Care and Neurobiology Centre, Department of Neurology Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry India., Babu Phaniti P; Department of Biotechnology & School of Medical Sciences University of Hyderabad Hyderabad India., Babu Chidambaram S; Department of Pharmacology JSS Medical College Mysore India., Rachel Vasanthi AH; Department of Biotechnology School of Life science University of Pondicherry Pondicherry India., Arumugam M; Comprehensive Stroke Care and Neurobiology Centre, Department of Neurology Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry India.
Jazyk: angličtina
Zdroj: Animal models and experimental medicine [Animal Model Exp Med] 2021 Apr 23; Vol. 4 (2), pp. 104-115. Date of Electronic Publication: 2021 Apr 23 (Print Publication: 2021).
DOI: 10.1002/ame2.12166
Abstrakt: Despite the impressive efficacies demonstrated in preclinical research, hundreds of potentially neuroprotective drugs have failed to provide effective neuroprotection for ischemic stroke in human clinical trials. Lack of a powerful animal model for human ischemic stroke could be a major reason for the failure to develop successful neuroprotective drugs for ischemic stroke. This review recapitulates the available cerebral ischemia animal models, provides an anatomical comparison of the circle of Willis of each species, and describes the functional assessment tests used in these ischemic stroke models. The distinct differences between human ischemic stroke and experimental stroke in available animal models is explored. Innovative animal models more closely resembling human strokes, better techniques in functional outcome assessment and better experimental designs generating clearer and stronger evidence may help realise the development of truly neuroprotective drugs that will benefit human ischemic stroke patients. This may involve use of newer molecules or revisiting earlier studies with new experimental designs. Translation of any resultant successes may then be tested in human clinical trials with greater confidence and optimism.
Competing Interests: The authors have no conflict of interest.
(© 2021 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.)
Databáze: MEDLINE
Externí odkaz: